Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


AM-Pharma announces loan of up to €5 million from Dutch Government
Dutch Government supports AM-Pharma in development of first drug against Acute Kidney Injury


Bunnik, The Netherlands, 19 March, 2009. AM-Pharma B.V., the biopharmaceutical company developing endogenous proteins to combat disease, today announced it is receiving a loan of up to €5 million from SenterNovem, an agency of the Dutch Ministry of Economic affairs.

The loan is granted to support development of AM-Pharma’s Recombinant Optimized Human Alkaline Phosphatase as a treatment for Acute Kidney Injury, a medical condition responsible for the death of approximately seven hundred thousand people per year in the western world.

SenterNovem has provided the loan to AM-Pharma under the recently implemented InnovatieKrediet scheme. AM-Pharma is the first Dutch biotechnology company to benefit from this new facility. An initial amount of €2.25m has been committed for product manufacturing and will be paid out in advance of a number of agreed development milestones. A further €2.75m for subsequent clinical development up to Phase II Proof of Concept can be requested by AM-Pharma in 2010. This interest bearing loan will have to be repaid only after successful development of the product.

Bart Wuurman, CEO commented: “I am very proud that AM-Pharma is the first Dutch biotech company to benefit from this scheme. This type of financing is important to us as it will further strengthen the funding of our company. We also see this loan as recognition of the high medical importance of the drug we are developing against Acute Kidney Injury.”

-Ends-

Notes to editors:

About AM-Pharma www.am-pharma.com
AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of novel compounds in the field of severe inflammatory diseases. Its products are based on optimized endogenous proteins which combat disease using physiological defence mechanisms.

AM-Pharma has used Alkaline Phosphatase extracted from cow’s intestines to show that Alkaline Phosphatase has a beneficial effect on Acute Kidney Injury and on severe Ulcerative Colitis. After these positive results with this experimental bovine material, Recombinant Optimized Human Alkaline Phosphatase is now being manufactured for further development and commercialization.

AM-Pharma is based in Bunnik, The Netherlands with a staff of 9. The company is financed by Forbion Capital Partners and Inventages Venture Capital. Once product safety and efficacy have been established with Recombinant Optimized Human Alkaline Phosphatase in Phase II trials, AM-Pharma intends to out-license its products to partners for further development and world wide marketing.

About Acute Kidney Injury

Hospital-acquired Acute Kidney Injury (AKI) occurs in as many as 4% of hospital admissions and 20% of critical care admissions. The incidence is increasing because of an aging population, the increasing exposure to nephrotoxic drugs in hospitals, and increasing number of surgical interventions. Depending on the severity of renal failure, the mortality rate ranges from 7% to as high as 80%. Annually around 700,000 patients die of Acute Kidney Injury in Europe, US and Japan. Currently the only treatment options are dialysis and kidney replacement. No drugs are approved to treat this condition.

About SenterNovem and the InnovatieKrediet scheme www.senternovem.nl/innovatiekrediet

The InnovatieKrediet is a risk bearing loan intended to finance commercially attractive development projects with high risk. The supported projects are aimed at development of new products, processes or services. The InnovatieKrediet scheme reduces the financial risk to the entrepreneur. Should the project fail, repayment of the loan is waived. The loan has separate budgets for technical development and clinical development.

For further information, please contact

Corporate enquiries

AM-Pharma
CEO Bart Wuurman
Tel: +31 (0)30 2289222
www.am-pharma.com

Media enquiries

College Hill Life Sciences
Adam Michael / Justine Lamond / Benjamyn Tan
Tel: +44 (0)20 7866 7857
ampharma@collegehill.com


Publisher Contact Information:

College Hill Life Sciences
+44 (0)20 7866 7857
ampharma@collegehill.com

Company profile of AM-Pharma BV
Past press releases of AM-Pharma BV.

Data


27,526
Tech investments
From our Online Data Service
17,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.